MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The present trial is addressing the question if a biologically distinct subgroup of ischemic
stroke patients without known atrial fibrillation at admission, selected by a cut-off level
of MRproANP concentration, which represents a underlying increased risk of cardiac
thrombogenicity, benefits from direct oral anticoagulation (DOAC) versus antiplatelets as
preventive treatment.